Phase A — Understand the business
Lens 1 · Company Overview
FormFactor sells the pick-and-shovel of chip test: it does not make chips, it makes the precision interface that touches a wafer and tells you whether the silicon works. Three things to internalize:
- It is a probe-card company first, everything else second. Two reportable segments — Probe Cards ($637.9M, 81% of FY2025 revenue) and Systems ($147.1M, 19%). Within Probe Cards, the markets are Foundry & Logic ($369.9M), DRAM ($247.4M), and Flash ($20.6M). The 10-K is blunt: "We derive the majority of our revenues from the sale of our probe card products… We anticipate that sales of probe cards will represent a substantial majority of our revenues for the foreseeable future". Systems (probe stations, thermal chucks, cryogenic systems) is the "Lab" half of the "Lab-to-Fab" story — strategically interesting (quantum, photonics) but a minority of the P&L.
- The product is a custom consumable, not a tool. A probe card is engineered to one customer's specific wafer/chip design and wears out over "hundreds of thousands, even millions, of compression cycles". Present tech puts >150,000 contact elements on a card at 40-micron spacing, testing at >80 GHz. That custom-consumable structure is the whole investment case: more complex chips → more test content → more probe cards per wafer, and they get replaced.
- The end markets are exactly the AI-infrastructure stack. Customers test GPUs/CPUs/custom ASICs (Foundry & Logic), HBM/DRAM, NAND, RF, image sensors, co-packaged optical ICs, and quantum processors. The growth engine right now is HBM (memory stacks for AI accelerators).
Contract structure: revenue recognized at point of control transfer (ship/deliver); no take-or-pay, generally purchase-order driven with installation/service contracts (1–3 yr) as separate performance obligations. Because cards are custom, cancellations create non-recoverable cost / inventory impairment — a real downside-asymmetry the company flags itself. Founded 1993, HQ Livermore CA, ~2,153 employees, Mike Slessor CEO. No dividend.
Lens 2 · Supply Chain
Map: upstream component/material suppliers → FormFactor manufacturing → chipmaker/foundry → AI accelerator → hyperscaler.
- Upstream into FORM (named chokepoints): the 10-K states it depends on suppliers for "ceramic and organic substrates and complex printed circuit boards" and certain "contact elements and interconnects," some single-vendor / sole-source, generally on purchase orders, not long-term contracts — explicitly flagged as a price-increase and shortage risk. In Feb 2025 FORM bought a 20% equity stake in FICT Limited (Nagano, Japan) — a maker of complex multi-layer organic substrates and PCBs. Read that as vertical-integration insurance on its single most strategic input (the organic substrate that carries the probe). It cost $67.2M of cash in FY2025 and is currently dilutive — $2.0M equity-method loss in FY2025.
- FORM manufacturing footprint: probe cards in Livermore CA + Beaverton OR (primary), smaller Yokohama JP; Carlsbad + Baldwin Park CA being consolidated/closed by end-FY2026; a new Farmers Branch, Texas site (50,000 sq ft cleanroom, four structures) ramping late-FY2026. Systems/thermal/cryo in Boulder CO + Thiendorf/Munich/Karlsruhe Germany.
- Downstream named customers (this is where it's concentrated): SK hynix (>10% of revenue in every one of the last 8 quarters, 19.2%–25.0%), Intel (12–17% in several quarters), TSMC (10.4% in Q2-25), Samsung (12.4% in Q1-24). NVIDIA disclosed as a 10%+ customer for the first time in Q1-26 at 10.2%, with SK hynix at 29.5%. So the chain terminates squarely in the HBM→Nvidia-accelerator→hyperscaler loop.
- Chokepoint verdict: FORM is itself a chokepoint (one of three firms that can do leading-edge MEMS probe cards), but it sits on a thin sole-sourced substrate supply and a customer base of three or four giants. Concentration risk runs in both directions.
Lens 3 · Competitive Advantages (moats)
Real but contested — a "narrow moat that is being actively attacked."
- Source of the moat: (1) Customer-specific qualification. Each card is co-designed to a customer's wafer; the 10-K names "high capital investment… and the time and high cost of the customer evaluation process" as the barrier to entry in MEMS probe cards. Once you're qualified into a device family, you're sticky for that family's life. (2) High-frequency / high-parallelism leadership — >80 GHz, >150k contacts — which the company argues is what lets it win HBM (testing stacks of 8/12/16 DRAM die). (3) Lab-to-Fab breadth — it is the only player spanning analytical probes, probe stations, cryogenic systems AND production probe cards, giving it the photonics/quantum optionality rivals lack.
- Bargaining power: weak-to-balanced vs customers (a handful of giants, custom product, cancellable orders → customers hold the whip), and mixed vs suppliers (sole-source substrates → suppliers hold pricing power, which is exactly why FORM bought into FICT).
- The moat-erosion fact you cannot ignore: Technoprobe's fully-integrated MEMS-tip production won ~30% of TSMC's 2nm qualifications, "eroding FormFactor's historical lead" in foundry probe cards. FORM's own FY2025 Foundry & Logic revenue fell 3.0% while the AI cycle roared — a yellow flag that the moat is strongest in memory/HBM and weakest where Technoprobe is pressing.
- Verdict: durable in HBM and high-parallelism memory (Smart Matrix is a genuine edge); contested and slipping in leading-edge foundry. Not a wide moat — a capability lead that must be continuously re-earned each node.
Lens 4 · Segments
All `` unless noted.
| Segment / Market | FY2023 | FY2024 | FY2025 | FY25 trend |
|---|
| Probe Cards (total) | $497.9M | $626.0M | $637.9M | +1.9% — decelerating sharply |
| — Foundry & Logic | $363.5M | $381.2M | $369.9M | −3.0% (weak client/server CPU) |
| — DRAM | $113.8M | $227.4M | $247.4M | +8.8% (HBM-led; +99.9% in FY24) |
| — Flash | $20.6M | $17.4M | $20.6M | +18.7% (set to shrink, Baldwin Park closing) |
| Systems | $165.2M | $137.6M | $147.1M | +6.9% (off a FRT-sale-depressed base) |
| Total | $663.1M | $763.6M | $785.0M | +2.8% |
Segment gross margin: Probe Cards 37.2% (FY23) → 41.4% (FY24) → 40.5% (FY25); Systems 51.3% → 43.2% → 41.8% (Systems margin has halved its premium as mix shifted to lower-margin products). Within Probe Cards, DRAM is structurally lower margin than Foundry & Logic, so the HBM-driven mix shift (DRAM 36.3%→38.8% of probe-card sales) is a margin headwind even as it's a growth tailwind — a key tension.
Geography: South Korea 30.3% (HBM/SK hynix), Taiwan 25.8% (foundry/TSMC), US 19.4%, China 7.4% (down from 13.5% in FY24 — export controls), Japan 5.5%. The China decline is policy-driven, not demand-driven, and it's nearly done washing through.
The acceleration story is entirely in DRAM/HBM. Q1-FY2026 makes it vivid: total revenue +32% YoY to $226.1M, with DRAM probe-card revenue +70% YoY to $82.9M and Foundry & Logic +30% to $111.2M. Systems actually fell 20% YoY ($34.8M→$27.9M) as legacy probe stations gave way ahead of the Triton CPO ramp.
Phase B — Measure performance
Lens 5 · Earnings Result (latest print: Q1-FY2026, period ended 2026-03-28)
A genuine beat-and-raise, partially masked by a restructuring charge in GAAP.
- Revenue $226.1M, +32.0% YoY (vs $171.4M); above the company's $220–230M guide and a Q1 record.
- Gross profit $86.8M, GAAP GM 38.4% — but COGS absorbed $21.5M of 2026-restructuring charges; underlying GM ≈ 47.9%. Probe Cards segment GM hit 50.5% (vs 37.8% a year ago) — the operationally important number.
- Operating income $16.6M (GAAP) vs $3.3M; net income $20.4M (+218%); GAAP diluted EPS $0.26 vs $0.08. Non-GAAP diluted EPS was $0.56 — the gap is restructuring + SBC + amortization. Always read FORM on non-GAAP for run-rate, but respect that GAAP operating margin is structurally only ~7%.
- Guidance (Q2-FY2026): revenue $240M ±5M, non-GAAP GM 49.5% ±150bp, non-GAAP EPS $0.61 ±0.04; HBM guided to "another record" as a second customer adopts Smart Matrix for at-speed stack test. Tone: clearly upbeat / accelerating.
- Balance-sheet flags: cash $123.5M + marketable securities $179.7M = ~$303M; AR $132.2M (up with revenue — not outrunning it); inventory $112.9M (well-controlled, +2% q/q on +revenue); goodwill $215.4M; minimal term debt. CFO Q1 $45.0M vs $23.5M — operating cash nearly doubled. Healthy.
- Market reaction: despite the beat-and-raise, the stock fell ~11.6% in late April — pre-earnings profit-taking after a ~354% 12-month run and valuation vertigo. The print was good; the stock was priced for perfect. That is the single most important sentence in this dossier.
Lens 6 · Earnings Calls (sentiment trend)
No transcripts on the local shelf (transcripts/ empty) — this lens is ``, drawn from Q4-25 and Q1-26 call coverage.
- Tone trajectory (last ~3 calls): Q3-25 → Q4-25 → Q1-26 shows steadily rising confidence, with the vocabulary migrating from "cyclical recovery / diversification" to "HBM4 inflection," "Smart Matrix adoption," and "record". Q4-25 stock +14.4% on a raised 2026 outlook.
- What management keeps repeating: HBM test-intensity, Smart Matrix full-wafer contactor for HBM4, the Triton CPO platform (co-developed with Advantest + Tokyo Electron), the "$1.6B revenue / doubling by 2030" long-range target. Capital-allocation language centers on the Texas factory build and gross-margin discipline.
- What they've stopped emphasizing: the China/export-control drag (now small at ~5–7% of revenue) and Systems-segment growth (de-emphasized while it transitions to CPO). The narrative has become purely an AI-memory-test story — which is both the bull case and the concentration risk.
Lens 7 · Comps
| Company | Ticker | Mkt cap (USD) | EV/Sales | EV/EBITDA | Fwd P/E | Div yld | Source |
|---|
| FormFactor | FORM | ~$11.0B | ~11.5x | ~27x fwd / 70–84x ttm (restructuring-distorted) | ~57x | 0% | research-layer + web |
| Technoprobe | TPRO (Milan) | ~$26B | ~27.5x | ~43–69x | ~49x fwd | n/a | web |
| Teradyne | TER | n/a | n/a | n/a | n/a | — | |
| Advantest | 6857 (Tokyo) | n/a | n/a | n/a | n/a | — | |
| Micronics Japan | 6871 (Tokyo) | n/a | n/a | n/a | n/a | — | |
Read: the only directly-comparable public pure-play is Technoprobe, and it trades even richer than FORM (~$26B cap, ~49x fwd P/E) on €628.4M FY2025 revenue (+16%, net income €98.8M +55%). So the market is paying a structural premium for the probe-card duopoly's AI leverage — FORM is expensive, but not an outlier within its own niche. It IS an outlier vs the broader semi-cap group. The honest framing: FORM at ~57x forward earnings and ~11.5x EV/sales is priced as an AI-secular-grower, not as the ~18–20% cyclical test-equipment supplier its 10-year financials describe. ATE peers (Teradyne, Advantest) and the Japanese probe names would anchor the table properly but I could not source clean current multiples for them — flagged rather than fabricated.
Lens 8 · Stock-Price Catalysts (what actually moves FORM)
Mostly ; the 5-year total-return path is .
- 5-yr cumulative total return (from the 10-K's own performance graph, $100 invested 2020-12-26): $104.5 (2021) → $52.2 (2022) → $98.0 (2023) → $107.8 (2024) → $136.4 (2025). That 2022 halving is the tell.
- The pattern: FORM trades as a high-beta memory-cycle + AI-sentiment proxy. The >50% drawdown in 2022 mapped the DRAM/NAND oversupply and ~20% YoY semi-revenue decline; revenue itself fell 11.3% in 2023. The ~354% rally into 2026 mapped the HBM/AI capex super-cycle.
- What the market reacts to, ranked: (1) HBM/DRAM demand signals and HBM4 timing (the dominant driver now); (2) memory-customer capex (SK hynix/Samsung/Micron 2026 capacity is "sold out" ); (3) its own guidance vs a stretched bar — Q1-26 proves a beat-and-raise can still sell off ~12% when expectations are extreme; (4) export-control / China headlines (now muted). Earnings + HBM roadmap move this stock far more than valuation does — until a cycle turn, when valuation moves it violently.
Phase C — Judge people & books
Lens 9 · Management
- CEO Michael (Mike) Slessor — President Oct-2013, CEO since Dec-2014 (~11.5 yr tenure); joined via the 2012 MicroProbe acquisition (he was its CEO); prior KLA-Tencor. Track record: steered FORM from a ~$300M sub-scale probe-card maker through the 2022 trough to a $785M record-revenue, two-segment, Lab-to-Fab platform; 3-yr TSR to mid-2024 at the 73rd percentile of the S&P Semis index. Capital allocation has been acquisition-and-capacity, not return-of-capital: bought MicroProbe, Cascade Microtech, FRT (later sold), Keystone Photonics (Dec-2025, $20.6M, silicon-photonics test), the FICT 20% stake, and the Texas factory. Buybacks are modest and roughly offset dilution (see Lens 10).
- Skin in the game / comp: total comp ~$5.3M (≈11% salary, ≈89% equity/bonus); direct ownership
0.69% ($29.6M at recent prices). Founder? No — a professional operator who has run this asset for over a decade. For a serial-acquirer test-equipment platform, that's the right archetype; the risk is the empire-building bias acquirers carry.
- Red flags: none acute. The FICT minority stake is a related-supplier investment to watch (currently loss-making, $2.0M drag ); the acquisition cadence means goodwill is now $215.4M (~17% of assets). No comp scandal, no strategy whiplash, no promotional behavior in the disclosures.
Lens 10 · Forensic Red Flags
Forensic read of the income statement, balance sheet, and cash flow — every figure ``.
- Earnings quality / non-GAAP gap: the headline risk is the GAAP-vs-non-GAAP wedge. FY2025 SBC was $38.6M — i.e., 71% of the $54.4M GAAP net income. Non-GAAP EPS ($0.56 in Q1-26) flatters GAAP ($0.26) by adding back restructuring + SBC + amortization. This is normal for semi-cap, but at a ~57x non-GAAP multiple the SBC dilution is doing real work and must be counted. Share count is, to management's credit, flat (~77.3M diluted FY23→FY25) — buybacks ($26.2M FY25) roughly neutralize RSU/ESPP issuance, so the dilution is contained even if the expense is large.
- Gain-on-sale noise: FY2023 and FY2024 net income was inflated by one-time gains — $73.0M (FRT sale, FY23) and $20.6M (China ops sale, FY24). So the optics of "net income fell from $82.4M→$69.6M→$54.4M" is misleading — operating income ex-gains actually troughed and is now recovering. Watch that analysts don't anchor on the gain-boosted prior years.
- Cash flow vs earnings: clean. FY2025 CFO $115.4M comfortably exceeded GAAP net income $54.4M; FCF was depressed to ~$11.7M only because of one-time growth capex (Texas land/build) + the $67.2M FICT stake + $20.6M Keystone — i.e., investment, not deterioration. FY2024 FCF was ~$79.1M. AR and inventory are growing with — not ahead of — revenue (AR +$20.2M, inventory +$20.7M on +$21.4M revenue in FY25; well-behaved in Q1-26). No receivables/inventory red flag.
- Inventory provisioning: FORM books a steady ~$13–15M/yr excess-and-obsolete provision — appropriate given custom-card obsolescence; not aggressive, not suspiciously low.
- Effective tax rate rose to 18.7% (FY25) from 12.3% on OBBBA changes — a modeling input, not a flag.
Regulatory findings (required sub-section):
- SEC Litigation Releases / AAERs: None. Verified via SEC EDGAR EFTS (LR + AAER), search window 2021-06-30 to 2026-06-30.
- Non-SEC enforcement (FTC/DOJ/FDA/export): web search returned no enforcement action, lawsuit, or settlement against FormFactor. FORM is affected by US→China export controls (it lost China revenue, 13.5%→7.4%) but is a compliant party, not a target. ~7% of FY2025 revenue was China-derived, down from 14% FY2024, under the expanded license regime.
- 10-K Item 3 (Legal Proceedings): incorporates Note 12; the company discloses only "legal proceedings and claims in the ordinary course of business" with no specific material matter quantified.
- Conclusion: No material regulatory or legal findings — verified via SEC EDGAR EFTS (LR, AAER), web search, and 10-K Item 3 / 10-Q Note 15 as of 2026-06-30.
Phase D — Project & stress-test
Lens 11 · Forward Projection (FY2026 / FY2027 / FY2028 non-GAAP EPS)
Built bottom-up from FY2025 actuals + Q1-26 actual + Q2-26 guide. Every input labeled; output ``. No forecast.ts create in --watchlist mode (per skill rules) — the base call is logged below for Connor to commit on a /thesis pass.
Anchors: FY2025 revenue $785.0M, non-GAAP EPS ~$1.90–1.93 (TTM proxy); Q1-26 non-GAAP EPS $0.56 actual, Q2-26 guide $0.61 mid; consensus FY26 non-GAAP EPS ~$2.48 (range $2.21–2.64), FY27 ~$2.34 — note the Street's FY27 < FY26 print looks like a stale/cyclical-reversion estimate; treat with caution.
| Scenario | FY2026E rev | FY2026E non-GAAP EPS | FY2027E EPS | FY2028E EPS | Key assumptions |
|---|
| Bull | ~$1.00B (+27%) | ~$2.80 | ~$3.60 | ~$4.40 | HBM4 ramps hard, Smart Matrix wins ≥3 memory customers, non-GAAP GM →51%+, foundry stabilizes, CPO contributes |
| Base | ~$0.93B (+18.5%) | ~$2.50 | ~$2.85 | ~$3.20 | HBM4 ramps on schedule, GM ~49–50% non-GAAP, foundry flat, Texas start-up costs $20–25M absorbed in FY26 |
| Bear | ~$0.83B (+6%) | ~$1.70 | ~$1.40 | ~$1.55 | Memory cycle rolls in late-26/27, HBM digestion, Technoprobe takes more foundry, GM back to ~45%, Texas costs bite |
Margin bridge note: the base case hinges on the non-GAAP GM holding at the guided ~49.5% (vs FY2025's underlying ~40% blended / 47.9% Q1 underlying) — that step-up is the 2026 restructuring payoff (Carlsbad/Baldwin Park consolidation) plus HBM mix and utilization. If the restructuring doesn't convert to durable margin, the base collapses toward the bear. Capex of $140–170M in FY26 means FCF stays suppressed through the Texas build — this is not a FCF story until FY2027.
Base call to log on a /thesis pass (NOT logged here): FORM FY2026 non-GAAP EPS >= $2.45, p≈0.60, resolves 2026-12-26, tags formfactor,deep-dive.
Lens 12 · Bull vs Bear
Bull case. FormFactor is the only Western pure-play on rising test-intensity in AI silicon. The physics are on its side: every generation of HBM (8→12→16-high) and every chiplet/CPO design adds contacts, frequency, and test time, and the cards are consumables. Smart Matrix is a genuine technical lead for at-speed HBM4 stack test, with a second customer now adopting it. The customer set — SK hynix, NVIDIA, TSMC — is the exact list you'd want exposure to. Memory makers have sold out 2026 capacity and are booking 2027. Management's "$1.6B by 2030" doubling is aggressive but directionally credible given the HBM ramp. The 2026 restructuring is a real, self-help margin lever (49.5% guided non-GAAP GM). Balance sheet is fortress-clean (~$300M cash, negligible debt).
Bear case (2–3 things that could permanently impair, plus the priced-in problem).
- Customer concentration is worsening, not improving. SK hynix 29.5% + NVIDIA 10.2% = ~40% of revenue in two names in Q1-26. A single HBM roadmap slip at SK hynix, or NVIDIA dual-sourcing its test, removes a quarter of the business overnight. The custom-card model means lost designs are non-recoverable.
- Technoprobe is out-executing FORM in leading-edge foundry (~30% of TSMC 2nm quals ) and FORM's own Foundry & Logic revenue fell in FY2025. The "moat" is half a moat.
- It's a cyclical wearing a secular multiple. The 2022 share-price halving and 2023 revenue decline are recent history. At ~57x forward non-GAAP EPS and ~11.5x EV/sales, the stock has priced out the cycle. GAAP operating margin is structurally ~7%.
Pre-mortem (it's Dec-2027, the thesis broke — what happened?). HBM4 either pushed right or commoditized faster than test-content grew; SK hynix's 2027 capacity got digested and orders air-pocketed; Technoprobe extended from foundry into memory; the Texas factory ramped into a softening cycle, leaving fixed cost stranded; and the ~57x multiple compressed to ~25x even as EPS held — a −50% price move on no fundamental catastrophe, purely de-rating. That is the most likely way to lose money here.
Are multiples too high? Yes on an absolute and semi-cap-relative basis; no relative to the only pure-play peer (Technoprobe, ~49x fwd). The risk isn't that FORM is a bad business — it's that the entry price already assumes the bull case.
Contrarian view (what the market is refusing to see). Bulls treat HBM-driven DRAM growth as pure upside, but DRAM probe cards are structurally lower-margin than the foundry cards FORM is losing to Technoprobe. So the AI memory boom may grow revenue while diluting the margin mix — the opposite of the operating-leverage story embedded in the multiple. The bull narrative and the segment economics quietly disagree.
Lens 13 · Devil's Advocate (short-seller)
Dismantling the long.
- The revenue is renting three landlords. ~40% in SK hynix + NVIDIA; >10% concentration in SK hynix for 8 straight quarters. This isn't a diversified consumables annuity — it's a levered bet on two customers' HBM roadmaps. Custom cards mean a lost socket is gone for good.
- The moat is being breached where it matters most. Technoprobe's vertical MEMS-tip integration is winning the highest-value, leading-edge foundry quals (TSMC 2nm). FORM's foundry revenue is already declining. If memory is the only place the moat holds, FORM is a memory-cycle stock, not a secular compounder.
- Most dangerous underestimated competitor: Technoprobe — same MEMS tech, faster execution, richer balance-sheet runway, and now a foothold in FORM's crown-jewel accounts.
- Capital-allocation skeptic's note: the FICT 20% stake is a related-supplier investment that's currently losing money; goodwill is ~17% of assets after a decade of deals; the Texas factory is a $140–170M FY26 capex bet timed into a cycle that has burned this company before.
- What must hold for today's price: non-GAAP GM steps to ~50%+ and holds; HBM4 ramps on schedule with FORM (not Technoprobe) winning the memory share; foundry stops bleeding; and the ~57x multiple doesn't compress. That's four things, all of which have to go right.
- Down-20–30%-growth scenario: if FY27 revenue comes in ~20% below the bull (i.e., flat-to-down as a cycle rolls), EPS likely halves toward the bear ~$1.40–1.55 and the multiple de-rates simultaneously — a classic cyclical double-whammy, plausibly −50–60% peak-to-trough, exactly as 2022 demonstrated.
- Single permanent-impairment scenario: NVIDIA or SK hynix internalizes / dual-sources HBM test at scale, or a competing at-speed contactor leapfrogs Smart Matrix. Plausibility: low-to-moderate near-term, but non-trivial over 3 years given how fast Technoprobe moved in foundry.
Lens 14 · Management Questions (15, ordered by information value)
- SK hynix + NVIDIA are now ~40% of revenue — what is the concrete path to getting your top-two concentration below 30%, and over what timeframe?
- Technoprobe reportedly won ~30% of TSMC's 2nm probe-card qualifications. What is your current win-rate trend at leading-edge foundry nodes (N3/N2/A16), and where specifically are you losing?
- Smart Matrix HBM4 — how many memory customers are designed in today, what's the qualification pipeline, and what is your assumed HBM4 probe-card content uplift vs HBM3E?
- Walk us through the non-GAAP gross-margin bridge from ~48% to the ~49.5% guide and to a sustained 50%+ — how much is restructuring (one-time) vs mix vs utilization?
- DRAM cards are lower-margin than foundry cards. As HBM scales, does revenue mix structurally cap your blended margin, and how do you offset that?
- The Texas (Farmers Branch) factory: at what revenue level does it reach breakeven utilization, and what's the downside if the memory cycle softens during the ramp?
- What is your through-cycle FCF-conversion target once the Texas capex normalizes, and when does FCF re-inflect?
- The FICT 20% stake is currently loss-making — what's the strategic thesis, the path to profitability, and would you increase the stake or fully acquire?
- How replaceable are your sole-source substrate/interconnect suppliers, and what would a disruption cost in revenue and margin?
- The Triton CPO platform with Advantest/TEL is guided to only $10–20M in 2026 — what's the realistic 2028–2030 CPO TAM and your expected share?
- What share of probe-card demand is genuinely "AI test-intensity" (rising content) vs simply higher memory volume that reverses with the cycle?
- How exposed are you to a 2027 HBM digestion air-pocket if SK hynix/Samsung over-build 2026–27 capacity?
- Capital allocation: with ~$300M cash and the multiple where it is, why buybacks/M&A over a larger return of capital — and what's your M&A bar now?
- What is your assumed China revenue trajectory under the current export regime, and is there further downside if controls tighten?
- At today's valuation, what specific milestones over the next 12–18 months do you think the market is over-crediting, and where are you most likely to disappoint?